Drug Trial News

RSS

New nanoparticle SARS-CoV-2 vaccine confers robust protection with single dose after two weeks

In a methodologically ‘state-of-the-art’ approach, US researchers have developed a protein-based nanoparticle vaccine against coronavirus disease (COVID-19), with a swift generation of antibodies and the potential to protect individuals who cannot receive other COVID-19 vaccines for medical reasons. The research is posted to the bioRxiv* preprint server.

5 Apr 2021

Phase 1 clinical study of unique vaccine to protect against COVID-19 begins

A unique vaccine to protect against COVID-19 begins clinical testing Tuesday, 6 April, at the Walter Reed Army Institute of Research (WRAIR), part of the U.S. Army Medical Research and Development Command.

5 Apr 2021

Researchers use new approach to detect high-risk Human Papilloma Virus

A study led by Queen Mary University of London researchers has compared the performance and acceptability of a urine test and four different vaginal self-sampling collection devices to detect high risk Human Papilloma Virus (HPV).

2 Apr 2021

Study investigates the efficacy of COVID-19 vaccines over longer term

COVID-19 vaccines were designed to reduce the likelihood that infection by the SARS-CoV-2 virus would lead to severe outcomes, such as hospitalization and death. In that sense, all of the currently approved vaccines -- Moderna, Pfizer and Johnson & Johnson -- have proven comparably effective.

2 Apr 2021

Antibodies produced from infection with SARS-CoV-2 501Y.V2 protect against other variants

A recent paper in the journal Nature shows that while earlier lineages do not elicit antibodies capable of efficiently neutralizing the newly emerged South African variant, SARS-CoV-2 501Y.V2 (B.1.351), the converse does occur.

31 Mar 2021

Oxford-AstraZeneca vaccine effective against B.1.1.7 SARS-CoV-2 variant

Published in The Lancet, the study explores if the Oxford-AstraZeneca vaccine works well in protecting against the B.1.1.7 variant, otherwise known as the U.K. variant.

31 Mar 2021

New Phase 1 clinical trial of investigational vaccine against B.1.351 SARS-CoV-2 variant begins

An investigational vaccine designed to protect against the B.1.351 SARS-CoV-2 variant has been administered as part of a new Phase 1 clinical trial evaluating the vaccine candidate's safety and immunogenicity in adult volunteers.

31 Mar 2021

Study compares performance of open-label placebo to blinded placebo in IBS patients

For decades, the power of the placebo effect was thought to lie in patients' belief that they were -- or at least, could be -- receiving a pharmacologically active treatment.

30 Mar 2021

The Dream Team opens clinical trial to find better treatment options for pancreatic cancer

A new team of pioneering pancreatic cancer researchers has been formed to predict which treatments might work best for individual pancreatic cancer patients based on the molecular traits of tumors.

30 Mar 2021

GlyNAC could improve many age-associated defects in older humans

A pilot human clinical trial conducted by researchers at Baylor College of Medicine reveals that supplementation with GlyNAC - a combination of glycine and N-acetylcysteine as precursors of the natural antioxidant glutathione - could improve many age-associated defects in older humans to improve muscle strength and cognition, and promote healthy aging.

29 Mar 2021

Type 2 diabetes drug can successfully reduce symptoms associated with tuberous sclerosis complex

A team of researchers led by UCL Great Ormond Street Institute of Child Health and Great Ormond Street Hospital (GOSH) has found that metformin - a drug commonly used to treat Type 2 diabetes - can successfully reduce symptoms associated with tuberous sclerosis complex (TSC), including reduction in the frequency of seizures and the size of brain tumors.

29 Mar 2021

Single Sputnik V vaccine dose elicits robust immune response in previously infected individuals

A new preprint research paper posted to the medRxiv server describes successful immunization of the vaccinated population with a single dose of the Russian-made Sputnik V vaccine.

29 Mar 2021

New ‘SINT1A‘ study explores potential of a probiotic to prevent type 1 diabetes in children

Type 1 diabetes is the most common metabolic disease in children and adolescents worldwide. It can be particularly dangerous as often there is no diagnosis until severe and sometimes life-threatening symptoms have already developed.

26 Mar 2021

Fluoxetine (Prozac) performs strongly in vitro against SARS-CoV-2 (including mutants)

Researchers from Finland, to expand on these studies, tested some of these drugs against the new SARS-CoV-2 variants. The study is published on the preprint server bioRxiv.

24 Mar 2021

CureVac's COVID-19 vaccine protects mice against emerging SARS-CoV-2 variants

The CVnCoV mRNA vaccine showed neutralizing antibody levels and completely protected mice infected with the B.1.351 variant. No viral genomes were seen in oral swabs, lungs, or brain.

23 Mar 2021

Study shows single dose of mRNA vaccine may suffice for those with prior SARS-CoV-2 infection

A recent study by researchers from Philadelphia, currently available on the medRxiv preprint server, shows that individuals with prior infection caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) exhibit substantial immune memory and develop a robust response to the first dose of an mRNA vaccine.

23 Mar 2021

Single BNT162b2 mRNA dose induces humoral and T cell responses against mutated variants with a history of COVID-19

In a paper recently uploaded to the preprint server bioRxiv by Tauzin et al. (March 18th, 2021) the ability of a single dose of mRNA vaccine to induce humoral and T cell responses against mutated variants are demonstrated and found to be reinforced in individuals with a history of COVID-19.

22 Mar 2021

RedHill provides opaganib treatment under compassionate use exemption for Swiss COVID-19 patients

RedHill Biopharma Ltd., a specialty biopharmaceutical company, today announced that it has acted on a request to provide opaganib treatment on an outpatient basis under compassionate use exemption for several Swiss patients suffering from COVID-19 pneumonia.

22 Mar 2021

AstraZeneca's COVID-19 vaccine protects against symptomatic disease

Results from a large clinical trial in the United States and South America indicate that AstraZeneca's COVID-19 vaccine, AZD1222, is well-tolerated and protects against symptomatic COVID-19 disease, including severe disease or hospitalization.

22 Mar 2021

Clofazimine inhibits coronaviruses including SARS-CoV-2, study finds

Researchers at the University of Hong Kong found that Clofazimine, a lipophilic antimicrobial riminophenazine dye used in combination with agents like rifampicin and dapsone to treat leprosy, inhibits coronaviruses, including the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19 disease.

21 Mar 2021

Previous
1
...
54
55
56
57
58
59
60
...
1143
Next

Drug Trial News

New nanoparticle SARS-CoV-2 vaccine confers robust protection with single dose after two weeks

Phase 1 clinical study of unique vaccine to protect against COVID-19 begins

Researchers use new approach to detect high-risk Human Papilloma Virus

Study investigates the efficacy of COVID-19 vaccines over longer term

Antibodies produced from infection with SARS-CoV-2 501Y.V2 protect against other variants

Oxford-AstraZeneca vaccine effective against B.1.1.7 SARS-CoV-2 variant

New Phase 1 clinical trial of investigational vaccine against B.1.351 SARS-CoV-2 variant begins

Study compares performance of open-label placebo to blinded placebo in IBS patients

The Dream Team opens clinical trial to find better treatment options for pancreatic cancer

GlyNAC could improve many age-associated defects in older humans

Type 2 diabetes drug can successfully reduce symptoms associated with tuberous sclerosis complex

Single Sputnik V vaccine dose elicits robust immune response in previously infected individuals

New ‘SINT1A‘ study explores potential of a probiotic to prevent type 1 diabetes in children

Fluoxetine (Prozac) performs strongly in vitro against SARS-CoV-2 (including mutants)

CureVac's COVID-19 vaccine protects mice against emerging SARS-CoV-2 variants

Study shows single dose of mRNA vaccine may suffice for those with prior SARS-CoV-2 infection

Single BNT162b2 mRNA dose induces humoral and T cell responses against mutated variants with a history of COVID-19

RedHill provides opaganib treatment under compassionate use exemption for Swiss COVID-19 patients

AstraZeneca's COVID-19 vaccine protects against symptomatic disease

Clofazimine inhibits coronaviruses including SARS-CoV-2, study finds

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Latest News